Join Our Team

Careers

APCaRI > Blog > Careers

Join Our Team

The successful clinical translation of new technologies to the clinic requires a wide range of expertise. Our multi-disciplinary group of more than 100 prostate cancer scientists, physicians, trainees and healthcare employees from five leading Alberta health research institutions are working with an international collaborative network to achieve our translational research goals – to make a meaningful impact on health policy and the outcomes of patients living with prostate cancer.

Our overall goal is to improve patient outcomes and quality of life by developing and successfully translating to the clinic innovative tests that are more sensitive, more accurate and more cost-effective than current tests for prostate cancer.

Submit Your Resume

  • Accepted file types: pdf, doc, rtf, Max. file size: 192 MB.
    .pdf, .doc, .rtf

New platform for prostate cancer diagnosis to be presented at ISEV 2017

The Lewis Research Group will present exciting results about new blood tests for prostate cancer during 3 talks at the upcoming 2017 International Society of Extracellular Vesicles (ISEV) annual meeting in Toronto (May 18-21). ISEV is a global society of researchers studying exosomes and microvesicles, which are the exciting new focus of cancer therapy and diagnosis.

Dr. Desmond Pink will speak about “Microflow cytometry: The Apogee A50 is a sensitive standard tool for extracellular vesicle analyses in liquid biopsies”, Robert Paproski’s presentation is entitled “Using machine learning of extracellular vesicle flow cytometry to build predictive fingerprints for prostate cancer diagnosis”, and Dr. John Lewis will speak about “An extracellular vesicle blood fingerprint distinguishes between patients with indolent and aggressive prostate cancer at diagnosis”.

The team is looking forward to sharing these key advances that were made possible through the APCaRI prospective cohort.

- John Lewis